Mesoblast Limited (MESO) News

Mesoblast Limited (MESO): $6.03

0.50 (+9.04%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Filter MESO News Items

MESO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MESO News Highlights

  • For MESO, its 30 day story count is now at 2.
  • Over the past 25 days, the trend for MESO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG, COIN and EAT are the most mentioned tickers in articles about MESO.

Latest MESO News From Around the Web

Below are the latest news stories about MESOBLAST LTD that investors may wish to consider to help them evaluate MESO as an investment opportunity.

5 Stocks to Ride the Santa Claus Rally

Mesoblast (MESO), Coinbase (COIN), Western Gas (WES), JAKKS Pacific (JAKK), and Brinker International (EAT) have the potential to outperform in the seven-day period.

Yahoo | December 21, 2023

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the United States Food and Drug Administration (FDA) for its allogeneic cell therapy Revascor® (rexlemestrocel-L) in the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). The filings were b

Yahoo | November 26, 2023

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.

Yahoo | November 23, 2023

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, has entered into an agreement to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil® (remestemcel-L) in the treatment of adults with steroid-refrac

Yahoo | November 21, 2023

Most Shareholders Will Probably Find That The Compensation For Mesoblast Limited's (ASX:MSB) CEO Is Reasonable

Key Insights Mesoblast's Annual General Meeting to take place on 28th of November Salary of US$672.7k is part of CEO...

Yahoo | November 21, 2023

Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?

Avid Bioservices (CDMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | November 15, 2023

While institutions own 25% of Mesoblast Limited (ASX:MSB), individual investors are its largest shareholders with 57% ownership

Key Insights Mesoblast's significant individual investors ownership suggests that the key decisions are influenced by...

Yahoo | November 9, 2023

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023. Mesoblast Chief Executive Silviu Itescu said: “During the period we had a very productive meeting with the United States Food and Drug Administration (FDA), which has allowed us to establish the path forward for potential pediatric and adult approvals of Ryo

Yahoo | October 31, 2023

When Will Mesoblast Limited (ASX:MSB) Breakeven?

With the business potentially at an important milestone, we thought we'd take a closer look at Mesoblast Limited's...

Yahoo | October 18, 2023

10 Best ASX Stocks To Invest In

In this article, we take a look at the 10 best ASX stocks to invest in. If you want to see more stocks listed on the ASX, go directly to the 5 Best ASX Stocks To Invest In. Australia, formally known as the Commonwealth of Australia, is an independent nation encompassing the primary landmass of […]

Yahoo | September 30, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!